Literature DB >> 12021827

Chronic citicoline increases phosphodiesters in the brains of healthy older subjects: an in vivo phosphorus magnetic resonance spectroscopy study.

S M Babb1, L L Wald, B M Cohen, R A Villafuerte, S A Gruber, D A Yurgelun-Todd, P F Renshaw.   

Abstract

RATIONALE: Phosphatidylcholine (PtdCho) in brain cell membranes decreases with age. Evidence from both animal and in vitro studies indicates that CDP-choline (citicoline) administration may increase phosphatidylcholine (PtdCho) synthesis and might reverse PtdCho loss.
OBJECTIVES: We investigated whether oral citicoline can increase PtdCho synthesis in the brains of older subjects by measuring levels of phosphorus-containing metabolites using proton-decoupled phosphorus magnetic resonance spectroscopy ((31)P-MRS) before and after citicoline treatment.
METHODS: All subjects took 500 mg citicoline once orally each day for 6 weeks, then took either citicoline or placebo once orally per day for a second 6-week period. Subjects underwent a (31)P-MRS scan at baseline and following 6 and 12 weeks of treatment.
RESULTS: Treatment with citicoline for 6 weeks was associated with a 7.3% increase from baseline levels in brain phosphodiesters ( P=0.008), including an 11.6% increase in glycerophosphoethanolamine ( P=0.002) and a 5.1% increase in glycerophosphocholine ( P=0.137). Subjects who continued to take citicoline for the second 6-week period did not show significant additional increases in the levels of these metabolites. No changes were seen in other phosphorus-containing metabolites. There was a correlation between improvement on the California Verbal Learning Test and increase in phosphodiesters.
CONCLUSIONS: The increases in phosphodiesters seen in this study indicate that phospholipid synthesis and turnover were stimulated by 6 weeks of oral citicoline. These results in humans support previous in vitro and animal studies and suggest that the administration of oral citicoline may be of use in reversing age-related changes in the brain.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12021827     DOI: 10.1007/s00213-002-1045-y

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  13 in total

1.  Short-term administration of uridine increases brain membrane phospholipid precursors in healthy adults: a 31-phosphorus magnetic resonance spectroscopy study at 4T.

Authors:  Nivedita Agarwal; Young-Hoon Sung; J Eric Jensen; Grace daCunha; David Harper; David Olson; Perry F Renshaw
Journal:  Bipolar Disord       Date:  2010-12       Impact factor: 6.744

Review 2.  Differential aging of the brain: patterns, cognitive correlates and modifiers.

Authors:  Naftali Raz; Karen M Rodrigue
Journal:  Neurosci Biobehav Rev       Date:  2006-08-17       Impact factor: 8.989

3.  Improvements in concentration, working memory and sustained attention following consumption of a natural citicoline-caffeine beverage.

Authors:  Steven E Bruce; Kimberly B Werner; Brittany F Preston; Laurie M Baker
Journal:  Int J Food Sci Nutr       Date:  2014-07-21       Impact factor: 3.833

Review 4.  Citicoline in addictive disorders: a review of the literature.

Authors:  Nicholas D Wignall; E Sherwood Brown
Journal:  Am J Drug Alcohol Abuse       Date:  2014-06-20       Impact factor: 3.829

5.  Effects of daily treatment with citicoline: a double-blind, placebo-controlled study in cocaine-dependent volunteers.

Authors:  Stephanie C Licata; David M Penetar; Caitlin Ravichandran; John Rodolico; Christopher Palmer; Jeff Berko; Thomas Geaghan; Alison Looby; Erica Peters; Elizabeth Ryan; Perry F Renshaw; Scott E Lukas
Journal:  J Addict Med       Date:  2011-03       Impact factor: 3.702

6.  Energetic and cell membrane metabolic products in patients with primary insomnia: a 31-phosphorus magnetic resonance spectroscopy study at 4 tesla.

Authors:  David G Harper; David T Plante; J Eric Jensen; Caitlin Ravichandran; Orfeu M Buxton; Kathleen L Benson; Shawn P O'Connor; Perry F Renshaw; John W Winkelman
Journal:  Sleep       Date:  2013-04-01       Impact factor: 5.849

7.  Tissue-specific differences in brain phosphodiesters in late-life major depression.

Authors:  David G Harper; J Eric Jensen; Caitlin Ravichandran; Yusuf Sivrioglu; Marisa Silveri; Dan V Iosifescu; Perry F Renshaw; Brent P Forester
Journal:  Am J Geriatr Psychiatry       Date:  2013-01-11       Impact factor: 4.105

8.  Neurochemical alterations in methamphetamine-dependent patients treated with cytidine-5'-diphosphate choline: a longitudinal proton magnetic resonance spectroscopy study.

Authors:  Sujung J Yoon; In Kyoon Lyoo; Hengjun J Kim; Tae-Suk Kim; Young Hoon Sung; Namkug Kim; Scott E Lukas; Perry F Renshaw
Journal:  Neuropsychopharmacology       Date:  2009-12-30       Impact factor: 7.853

9.  The citicoline brain injury treatment (COBRIT) trial: design and methods.

Authors:  Ross Zafonte; William T Friedewald; Shing M Lee; Bruce Levin; Ramon Diaz-Arrastia; Beth Ansel; Howard Eisenberg; Shelly D Timmons; Nancy Temkin; Thomas Novack; Joseph Ricker; Randall Merchant; Jack Jallo
Journal:  J Neurotrauma       Date:  2009-12       Impact factor: 5.269

10.  Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

Authors:  Eri Nakazaki; Eunice Mah; Kristen Sanoshy; Danielle Citrolo; Fumiko Watanabe
Journal:  J Nutr       Date:  2021-08-07       Impact factor: 4.798

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.